Abstract
Recent evidence demonstrated that dysregulation of adipocytokine functions seen in abdominal obesity may be involved in the pathogenesis of the metabolic syndrome. Angiotensinogen, the precursor of angiotensin (Ang) II, is produced primarily in the liver, and also in adipose tissue, where it is up-regulated during the development of obesity and involved in blood pressure regulation and adipose tissue growth. Blockade of renin-angiotensin system (RAS) attenuates weight gain and adiposity by enhanced energy expenditure, and the favorable metabolic effects of telmisartan have been related to its Ang II receptor blockade and action as a partial agonist of peroxisome proliferators activated receptor (PPAR)-γ. PPARγ plays an important role in regulating carbohydrate and lipid metabolism, and ligands for PPARγ can improve insulin sensitivity and reduce triglyceride levels. Similarly, bone metabolism is closely regulated by hormones and cytokines, which have effects on both bone resorption and deposition. It is known that the receptors of Ang II are expressed in culture osteoclasts and osteoblasts, and Ang II is postulated to be able to act upon the cells involved in bone metabolism. In in vitro system, Ang II induced the differentiation and activation of osteoclasts responsible for bone resorption. Importantly, it was demonstrated by the sub-analysis of a recent clinical study that the fracture risk was significantly reduced by the usage of angiotensinconverting enzyme inhibitors. To treat the subgroups of hypertensive patients with osteoporosis RAS can be considered a novel target.
Keywords: Angiotensin II, adipose tissue, obesity, osteoporosis, osteoclast.
Current Pharmaceutical Design
Title:Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone
Volume: 19 Issue: 17
Author(s): Hironori Nakagami, Mariana Kiomy Osako and Ryuichi Morishita
Affiliation:
Keywords: Angiotensin II, adipose tissue, obesity, osteoporosis, osteoclast.
Abstract: Recent evidence demonstrated that dysregulation of adipocytokine functions seen in abdominal obesity may be involved in the pathogenesis of the metabolic syndrome. Angiotensinogen, the precursor of angiotensin (Ang) II, is produced primarily in the liver, and also in adipose tissue, where it is up-regulated during the development of obesity and involved in blood pressure regulation and adipose tissue growth. Blockade of renin-angiotensin system (RAS) attenuates weight gain and adiposity by enhanced energy expenditure, and the favorable metabolic effects of telmisartan have been related to its Ang II receptor blockade and action as a partial agonist of peroxisome proliferators activated receptor (PPAR)-γ. PPARγ plays an important role in regulating carbohydrate and lipid metabolism, and ligands for PPARγ can improve insulin sensitivity and reduce triglyceride levels. Similarly, bone metabolism is closely regulated by hormones and cytokines, which have effects on both bone resorption and deposition. It is known that the receptors of Ang II are expressed in culture osteoclasts and osteoblasts, and Ang II is postulated to be able to act upon the cells involved in bone metabolism. In in vitro system, Ang II induced the differentiation and activation of osteoclasts responsible for bone resorption. Importantly, it was demonstrated by the sub-analysis of a recent clinical study that the fracture risk was significantly reduced by the usage of angiotensinconverting enzyme inhibitors. To treat the subgroups of hypertensive patients with osteoporosis RAS can be considered a novel target.
Export Options
About this article
Cite this article as:
Nakagami Hironori, Osako Mariana Kiomy and Morishita Ryuichi, Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone, Current Pharmaceutical Design 2013; 19 (17) . https://dx.doi.org/10.2174/1381612811319170011
DOI https://dx.doi.org/10.2174/1381612811319170011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modelling of Aldose Reductase Inhibitory Activity of Pyrrol-1-yl-acetic Acid Derivatives by Means of Multivariate Statistics
Medicinal Chemistry Validated Spectrodensitometric Method for Simultaneous Estimation of Sofosbuvir, Ribavirin and Saxagliptin in their Pure and Pharmaceutical Dosage Forms
Current Pharmaceutical Analysis Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Roles of Calcium-Sensing Receptor (CaSR) in Renal Mineral Ion Transport
Current Pharmaceutical Biotechnology Herbal Medicine of the 21st Century: A Focus on the Chemistry, Pharmacokinetics and Toxicity of Five Widely Advocated Phytotherapies
Current Topics in Medicinal Chemistry Medical Therapy for Long QT Syndrome
Mini-Reviews in Medicinal Chemistry Determination of Manidipine in Human Plasma by UPLC–MS/MS and its Application to a Bioequivalence Study
Current Pharmaceutical Analysis Pesticides-induced Cardiovascular Dysfunctions: Prevalence and Associated Mechanisms
Current Hypertension Reviews Role of Apoptosis in the Pathogenesis of Contrast Media-induced Nephropathy and Hints for its Possible Prevention by Drug Treatment
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry The Role of Exhaled Nitric Oxide in the Diagnosis, Management and Treatment of Asthma
Mini-Reviews in Medicinal Chemistry Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus
Current Rheumatology Reviews Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Regioselective Synthesis of 2-Chloroquinoline Based Ethyl 4-(3- Hydroxyphenyl)-2,7,7-Trimethyl-5-Oxo-1,4,5,6,7,8-Hexahydroquinoline-3- Carboxylates and their In-Silico Evaluation Against P. falciparum Lactate Dehydrogenase
Medicinal Chemistry Neurotoxins: Free Radical Mechanisms and Melatonin Protection
Current Neuropharmacology The Role of COX-2 in Acute Pain and the Use of Selective COX-2 Inhibitors for Acute Pain Relief
Current Pharmaceutical Design Preface [Hot topic: Diabetes (Guest Editor: Alex M. DePaoli)]
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Treatment of the Motor and Non-Motor Symptoms in Parkinson's Disease According to Cluster Symptoms Presentation
Current Drug Targets